Today’s Solutions: December 19, 2025

The problem with any potential Covid-19 vaccine is that they are difficult to distribute in low-income and rural areas. Fortunately, researchers from Columbia University may have an effective alternative in the form of a nasal spray.

The spray is a lipopeptide (a lipid and peptide combination) that stops the coronavirus from fusing with a target cell’s membrane by blocking a key protein from adopting a necessary shape. It works immediately, lasts for at least 24 hours, and is affordable. Most importantly, it doesn’t need refrigeration, which is a big barrier for transporting vaccines to rural areas.

In tests so far, the researchers say it has successfully prevented COVID-19 infections in ferrets as well as a 3D model of human lungs. However, before the nasal spray reaches the public, the researchers still need to conduct human trials and figure out how to scale up the production of the spray.

Moving forward, the researchers are planning to “rapidly advance” further testing in order to deliver the nasal spray to parts of the world where mass COVID-19 vaccinations would be difficult.

Solutions News Source Print this article
More of Today's Solutions

Try this simple breathing exercise to rid yourself of cold hands and feet

Do you often find that your hands and feet are colder than the rest of your body? This can be perplexing, especially when gloves ...

Read More

Roman jars reveal the secrets of ancient winemaking

Archaeologists are still putting the full story of human history together. From the discovery of a Viking shipyard in Sweden to the Sistine Chapel ...

Read More

Cancer detection breakthrough revealed via butterfly-inspired imaging

In the world of sensory perception, other creatures frequently outperform humans. A research team has created an imaging sensor that looks into the elusive ultraviolet ...

Read More

Advancements in vision restoration: CRISPR gives hope to patients 

In a revolutionary development, CRISPR gene editing emerged as a beacon of hope for people suffering from genetic blindness. The results of a Phase ...

Read More